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SUMMARY
For the past decade, cancer genomic studies have focused on mutations leading to splice-site 
disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic 
tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 
TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of 
creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and 
ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and 
BAP1, were experimentally validated for splice-site-creating function. Notably, we found that 
neoantigens induced by SCMs are likely several folds more immunogenic compared to missense 
mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-
L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our 
work highlights the importance of integrating DNA and RNA data for understanding the functional 
and the clinical implications of mutations in human diseases.
In Brief
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Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000 
tumor samples across 33 cancer types. They provide a more accurate interpretation of previously 
misannotated mutations, highlighting the importance of integrating data types to understand the 
functional and the clinical implications of splicing mutations in human disease.
INTRODUCTION
Large-scale sequencing studies, such as The Cancer Genome Atlas (TCGA) project, have 
worked to address the functional consequences of genomic mutations in tumors (Dees et al., 
2012; Kandoth et al., 2013; Lawrence et al., 2013; Niu et al., 2016), with the larger goal of 
determining the underlying mechanisms of cancer initiation and progression. Many studies 
have focused on characterizing (1) non-synonymous somatic mutations that alter amino acid 
sequence and (2) splice-disrupting mutations at splice donors and acceptors (Jung et al., 
2015). Current annotation methods typically classify mutations as disruptors of splicing if 
they fall on either the consensus intronic dinucleotide splice donor, GT, or the splice 
acceptor, AG. As a group, splice site mutations have been presumed to be invariably 
deleterious because of their disruption of the conserved sequences that are used to identify 
exon-intron boundaries.
While this classification method has been useful, increasing evidence suggests that splice 
site mutations can lead to transcriptional changes beyond disruption of the canonical 
junction (Lim and Fairbrother, 2012; Mort et al., 2014; Rivas et al., 2015; Sauna and 
Kimchi-Sarfaty, 2011; Steffensen et al., 2014). One such example is the c.190 mutation in 
BRCA1. Conventional annotation had predicted a missense mutation, p.C64G, but our 
analysis of RNA sequencing (RNA-seq) data in ovarian tumors harboring p.C64G and a 
published mouse model (Yang et al., 2003) suggested the germline c.190 mutation leads to 
the creation of an alternative splice junction, resulting in a truncated null protein. Several 
case studies have reported observations of missense and silent mutations activating cryptic 
splice sites in MLH1 (Nyström-Lahti et al., 1999), LMNA (Woolfe et al., 2010), RB1 
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(Zhang et al., 2008), RNASEH2A (Rice et al., 2013), MECP2 (Sheikh et al., 2013), BAP1 
(Wadt et al., 2012), and KIT (Chen et al., 2005), and other studies relate missense and silent 
mutations to splicing changes (Jung et al., 2015; Kahles et al., 2016; Soemedi et al., 2017; 
Supek et al., 2014). Despite the broad clinical ramifications of mutation-induced altered 
splicing, a systematic evaluation of their occurrence and the resultant effects in cancer has 
yet to be undertaken, and there have not been significant bioinformatics platforms for doing 
so.
We developed a bioinformatic tool called MiSplice (mutation-induced splicing) that 
integrates DNA and RNA-seq data across thousands of samples to discover mutations that 
induce splice site creation. In our large-scale analysis across 8,656 tumor samples, we report 
1,964 such somatic mutations that had originally been mis-annotated. Splice-site-creating 
mutations (SCMs) are enriched in the new introns, with the highest rate at the −3 nt position 
of acceptors with two-thirds of such events at aGag and agGag repeats by creating an 
alternative junction 2 nt away. Partial and full splice creation capabilities across these 1,964 
sites were evaluated by measuring the fraction of reads supporting the alternative junction, 
which we termed the ‘‘junction allele fraction’’ (JAF) and which is found to be negatively 
correlated with distance to the new splice site. In total, 1,607 genes harbor SCMs, with 248 
of them having more than one mutation, including TP53, GATA3, ATRX, and NF1. 
Recurrent SCMs were found in TP53, GATA3, DDX5, KDM6A, PTEN, SETD2, SMAD4, 
BCOR, SPOP, and BAP1, suggesting an association with cancer development. Broadly 
speaking, integrated DNA and RNA data can furnish a sound basis for discovering SCMs 
and for accurately understanding functional consequences of mutations in cancer and in 
other human diseases.
RESULTS
Splice-Site-Creating Mutation Discovery
We collected high-quality mutation calls from 8,656 tumors across 33 cancer types derived 
from The Cancer Genome Atlas having available TCGA RNA-seq data (STAR Methods). 
For every mutation, we defined a set of control samples in the same cancer cohort that 
lacked the same mutation in the gene of interest. We sought to assess the landscape of SCMs 
across cancer genomes by evaluating all mutations already having conventional annotations 
and their potential splice-site-creating effects (Figure 1A). To achieve this goal, we 
conducted analysis using a bioinformatic tool, MiSplice (mutation-induced splicing), that 
systematically evaluates mutations in a splicing context using RNA-seq data (Figure 1B).
MiSplice manages large analyses using parallel computation to search for alternative splice 
junctions within windows of ±20 bp from the mutation of interest. For example, of the 
1,416,566 candidate mutations examined here, 4,448 had five or more unique RNA-seq 
reads supporting the predicted alternative junction in proximity to the mutation. MiSplice 
then conducts a series of further evaluations, including Ensembl-based filtering of canonical 
junctions, establishing observational significance by case comparison to a matched set of 
controls, and assessing score and depth of each cryptic site using MaxEntScan (Yeo and 
Burge, 2004) and SamTools (Li et al., 2009). From the resultant subset, MiSplice filters out 
human leukocyte antigen (HLA) genes and sites whose junctions have insufficient difference 
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of expression, as judged from the case-control assessment. Here, we evaluated promising 
alternative junctions with at least 5% of paired-end RNA-seq reads at the genomic location 
supporting the alternative junction of interest.
MiSplice processing revealed 2,056 mutations (Table S1) that potentially create an 
alternative splice site. Manual review indicated a 2.09% false-positive rate, suggesting high 
specificity of the MiSplice algorithm for discovering these types of mutation-induced 
splicing events. Of these putative splice events, 1.90% and 0.47% are considered complex 
and are in highly homologous gene regions, respectively, so they were excluded from further 
analyses (STAR Methods).
Of the final 1,964 SCMs passing manual review (Table S1), 52% (1,016) are in annotated 
splice sites, suggesting disruption of the canonical splice site and selection of a the 
alternative splice site nearby (Figure 1C). Importantly, 26% (513) and 11% (208) of the 
SCMs had previously been mis-annotated as missense and silent mutations, respectively. In 
addition, we found 58 insertions or deletions, 46 nonsense, and 123 non-coding region 
mutations that likewise create cryptic splicing sites.
Molecular and Biological Patterns of SCMs
Next, we characterized the sequence context for the 1,790 SCMs corresponding to single 
nucleotide mutations. The sequences of each 9-mer (donor) and 23-mer (acceptor) covering 
the mutation position were extracted for both the mutant and the reference sequences. Their 
splice scores as potential donor or acceptor sites were then estimated using MaxEntScan 
(Table S1).
Mutations near the alternative splice junctions show higher mutation rates in the introns for 
both 5′ (p < 1 × 10−5, binomial test) and 3′ splice site (p < 1 × 10−6) (Figure 2A). More 
interestingly, we found an enrichment of mutations at the third nucleotide position in the 
intron, but depletion at the first and second positions (especially for 3′ splice site) (Figure 
2A). Comparison of splicing scores between splice-site-creating mutants and reference 
forms shows that most mutants have stronger splice signals than the reference (Figure 2B). 
Mutations that create a G or T to produce an alternative 5′ splice site dramatically increase 
splice site strength. For 3′ splice sites, mutations enriched on the third nucleotide of the 
newly created intron showed the largest increase of splicing score (Figure 2B). Further 
examination of the sequence context around mutations at the third nucleotide of 3′ splice 
sites shows that 53% have a mutation on aGag repeats and another 16% are mutated on 
agGag repeats, all creating alternative junctions 2 nt away from the annotated ones (Figure 
2C). Mutations at the −3 position of the alternative acceptor site would potentially enhance 
U2AF1 recognition of the acceptor splice site. Previous studies have reported S34F U2AF1 
mutants preferentially skip exons that contain a T nucleotide at the −3 position (Okeyo-
Owuor et al., 2015). Of the 192 mutations located at the −3 position from the alternative 
junction and that contain an AG in the −2 and −1 positions, 56% undergo a G > C 
transversion (21%G > A, 18%G > T,3%C > T,2%A > C, 1% A > T), with C being the 
preferred base at the −3 position for U2AF1 binding (Figure 2D).
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We also explored the relationship between the alternative and canonical splice junctions. As 
expected, mutations at splice sites dramatically reduced splice scores of the canonical splice 
junctions, while strengthening those at the alternative splice junctions in most cases. In 
contrast, a subset of missense and silent mutations did not drastically alter the canonical 
junction, but instead preferentially strengthened a nearby alternative splice site (Figure 2E). 
When analyzing the raw splicing scores (canonical and alternative site before and after 
mutation), we found that 1,089 out of 1,790 (61%) events showed higher splice score for the 
alternative splice site than the canonical site, indicating inclination for the alternative sites. 
Further, while 485 (27%) events saw lower post-mutation alternative splice score, 
differences between alternative and canonical scores had decreased, suggesting that these 
mutations are still likely enhancing the preference for the alternative site. Only 214 (12%) 
events did not show evidence, suggesting increased post-mutational preference for using the 
alternative site. These cases are a good illustration of the fact that many other genomic 
splicing features are also relevant, including exonic splicing enhancers (ESE), 
polypyrimidine tract, branch point, and RNA-binding proteins. They are also consistent with 
the general view that splice score is not definitive (Jian et al., 2014). We emphasize that all 
1,790 alternative splice sites demonstrated usage based on patient RNA-seq data and that 10 
out of 11 (>90%) identified SCMs were validated experimentally (see below).
Expressivity and Penetrance of SCMs
In the presence of the mutation, alternative splice junctions exhibited a wide range of 
expression. To quantify this effect, we measured alternative junction expression as the 
fraction of alternatively spliced junction spanning reads over the total number of reads at the 
genomic location, what we refer to as the JAF. Figure 3A shows the distribution of JAF’s for 
all high confidence MiSplice predicted alternative junctions, separated by conventional 
mutation annotations (Figure 3A). Currently, we use a JAF cutoff of 5% for reporting the 
final high-confidence sites. However, there are some potential alternative sites excluded by 
this cutoff. Our analysis revealed alternative junction expression varies widely. As expected, 
DNA variant allele fraction (VAF) and JAF have a generally positive correlation (Figure 3B), 
with SCMs in KDM6A and FGFR2 having >75% DNA VAF and JAF. However, a SCM in 
ARID1A has a DNA VAF of 23% and JAF of 67%. Such large ranges have been noted for 
mutations outside of the splice site (Broeks et al., 2003; Clarke et al., 2000; Venables, 2004). 
Both the truncated and normal spliced products can be observed for many variants, due to 
either the wild-type allele or leaky splicing, for example, as observed in RNASEH2A, 
NFU1, SMN1, CFTR, and NF2 (Boerkoel et al., 1995; Caminsky et al., 2014; Ferrer-Cortès 
et al., 2016; Lohmann and Gallie, 2004; Mautner et al., 1996; Pagani et al., 2003; Rice et al., 
2013; Svenson et al., 2001; Vezain et al., 2011).
Next, we considered the expression of mutations that are spliced-in, i.e., mutations located 
within the exon of the alternatively spliced product. To this end, we determined the ratio of 
the number of alternative junction reads containing the mutation versus total number of 
reads supporting the alternative junction (Figure 3C; Table S1). Overall, most of the reads 
supporting the alternative junction also support the mutation, a finding that suggests a strong 
association between the mutation and alternative splice junction. Regarding the 5′ splice 
site, mutations within the first 6 bp of the new exon junction have a much higher fraction of 
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alternative junction reads supporting them; and we see an inverse correlation between the 
mutation and the junction as the distance between them increases. For the 3′ splice site, we 
observe a similar trend, although with a higher variability as a function of the distance from 
the alternative junction.
SCMs across Genes and Cancer Types
A total of 1,607 unique genes harbored SCMs, with 85% (1,359) having one mutation and 
15% (248) having two or more. TP53 contained the greatest number (26), followed by 
GATA3 (18). While most SCMs were found outside the current cancer gene compendium 
(Table S1), Figure 4A shows that a remarkable number of cancer genes harbor splice altering 
variants, a phenomenon supported in the literature (Sebestyén et al., 2016). A pan-cancer 
view reveals that TP53 was the most mutated across cancer types, while 18 GATA3 
mutations and 6 ATRX mutations were specific to breast cancer (BRCA) and lower-grade 
glioma (LGG), respectively.
We observed 137 mutations nearby to one another (±5 bp) which lead to the creation of the 
same recurrent splice-site-creating events, not only in TP53 but also in GATA3, DDX5, 
KDM6A, SETD2, PTEN, SPOP, and BAP1. While some mutations did not occur at the 
same position, 14 mutations creating the same alternative splice junction were found in the 
same exon, including 2 mutations in the third exon of BAK1. While most mutations in close 
proximity created the same alternative splice junction, two adjacent SCMs in CTNND1 and 
2 nearby exonic mutations in ACP2 and GMPPB created different alternative junctions.
SCMs can impact protein structure and have potential therapeutic implications. Poly ADP-
ribose polymerase 1 (PARP1) is an enzyme involved in recruiting protein members of DNA 
repair pathways including Timeless PAB (PARP1 binding domain) (Figure 4C) (Xie et al., 
2015). Since PARP1 is essential to many cellular processes, including DNA repair, it is 
commonly targeted by antitumor agents (Malyuchenko et al., 2015). PARP1 inhibitors 
targeting the catalytic domain disrupt DNA repair mechanisms thereby increasing the 
effectiveness of chemotherapeutic agents (Figure 4D). Identifying mutations that disrupt 
inhibitor binding are essential to properly evaluate treatment options. MiSplice identified a 
conventionally annotated silent PARP1 mutation (p.S939S) in a lung squamous cell 
carcinoma (LUSC) patient that acts as a splice-site-creating variant by creating a de novo 
donor site (Figure 5A). 82 reads supported the de novo donor site, which results in a 10 
amino acid deletion (p.940–p.950) that falls within the catalytic domain (Figure 4D). Out of 
173 LUSC control samples, none contained reads supporting the alternative junction, 
providing strong evidence that the annotated ‘‘silent’’ mutation is actually a SCM. Previous 
reports of missense mutations at p.940 are predicted to reduce PARP1 enzymatic activity by 
disrupting the binding affinity of PARP1 to its substrate NAD+ (Alshammari et al., 2014). 
The in-frame SCM likely disturbs the local structure of PARP1 and thereby disrupts the 
interactions between PARP1, its protein binding partners, and drugs binding within the 
pocket (Figures 4C and 4D).
We identified two kidney renal clear cell carcinoma (KIRC) samples having the same 
conventionally annotated missense mutation (c.233A > G, p.N78S) in BAP1, a nuclear 
deubiquitinase, that created the same spliced-out alternative splicing product (Figure 5B). 
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Inactivation of BAP1 is prevalent among renal cell carcinomas (Peña-Llopis et al., 2012) and 
an annotated missense mutation (p.L570V) has been reported to create a cryptic splice site in 
melanoma (Wadt et al., 2012). At the transcriptional level, the expressions of the case and 
control samples are relatively comparable, but at the translational level, one case with 
available protein data (RPPA) showed significantly lower expression (p = 0.044, permutation 
test) relative to the controls (Figure S1; Table S2). This result suggests the conventionally 
annotated missense mutations in BAP1 likely create an alternatively spliced transcript that is 
not readily expressed at the protein level.
We used a pCAS2.1 splicing reporter mini-gene functional assay that was adapted from 
previous publications (Bonnet et al., 2008; Gaildrat et al., 2010; Malone et al., 2016; 
Tournier et al., 2008; Vreeswijk and van der Klift, 2012), to validate SCMs in 11 cancer 
genes, including two originally annotated silent mutations in PARP1, RAD51C, two splice 
site mutations in TP53 and BRCA1, and several missense mutations in ARID2, BAP1, 
BCOR, CDH1, KMT2A, PTEN, and TSC2. Wild-type and mutant exons were cloned into a 
pCAS2.1 vector (Gaildrat et al., 2010) and transiently transfected into HEK293T cells. Total 
RNA was extracted to evaluate alternatively spliced products by RT-PCR. Examining the 
change in the MaxEntScan score for the 11 genes revealed mutations in ARID2, BAP1, 
BCOR, CDH1, PARP1, RAD51C, PTEN, and TSC2 having dramatically stronger splice 
scores in the presence of the mutation, while mutations in BRCA1, KMT2A, and TP53 did 
not (Figure 5D). Except for PTEN, variants with stronger splice scores showed higher levels 
of the alternatively spliced product in the mini-gene assay when compared to the wild-type. 
Variants with moderate changes in splice score still showed evidence of alternatively spliced 
transcripts, revealing the importance of utilizing functional assays to evaluate the effect of 
mutations in a splicing context in addition to in silico predictions. The minigene assay 
confirmed 91% (10/11 genes) splicing alterations in all tested genes and sequencing 
confirmed the alternatively spliced products (Figure 5E; STAR Methods), suggesting a 
strong concordance between MiSplice predicted SCMs and the functional assay.
Neoantigens Introduced by SCMs
We have further investigated neoantigens produced by SCMs. By using the RefSeq transcript 
database, a total of 2,993 protein sequences were translated for transcripts containing 
mutation-induced alternative splice forms (Table S3). In the translation, we allowed for 
different transcripts from each SCM. The HLA types for each sample were adopted from the 
TCGA pancan immune working group (Synapse ID: syn5974636). NetMHC4 and 
NetMHCpan-3.0 (Andreatta and Nielsen, 2016) were used to predict the binding affinity 
between epitopes and the major histocompatibility complex (MHC) and showed a high 
concordance in total predicted neoantigens (Pearson = 0.94; Figure S2). We found that 
alternative splice forms for some important genes related to tumorigenesis, including 
SMARC1, KDM6A, and NOTCH1, are highly immunogenic and can contain 40 or more 
unique neoantigens (Figure 6A) (Dalgliesh et al., 2010; Papadakis et al., 2015). In addition, 
the mean number of neoantigens across SCMs from NetMHCpan-4.0 and NetMHCpan-3.0 
are 2.0 and 2.5, respectively, which are both higher than the average number of around 1 for 
non-synonymous mutations. Furthermore, 28 genes contain recurrent neoantigen events (≥3) 
across samples (Figure 6B). In particular, GATA3 has the highest recurrence and GATA3 
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SCMs were mutually exclusive with other mutation types (Figure 6C). The CA deletion at 
chr8:8111433 disrupts the canonical splice site and an alternative splice site is used for 
creating the alternative splice form, which results in a frame shifted protein product 
spanning the Zinc-finger domain (Figures 6D and 6E). 19 unique neoantigen peptide 
sequences were mapped to the frameshifted protein product for the 16 samples (Figure 6F). 
We were further able to validate one alternative peptide sequence using mass spectrometry 
data from a recent proteogenomics study on 77 TCGA breast cancer patients (Mertins et al., 
2016). For one sample with the highly recurrent and expressed GATA3 SCM, we used 
MSGF+ to search publicly available mass spectrometry data for evidence of alternative 
GATA3 peptides. Figure 6G shows one identified mass spectrum supporting one alternative 
GATA3 peptide, which covers two immunogenic peptides (KPKRRLPG and 
LIKPKRRLPG) predicted in TCGA-AR-A1AP.
High neoantigen burden is associated with an elevated immune response (Turajlic et al., 
2017). To test whether SCMs affect immune response, we compared the expression of T cell 
markers PD-1, CD8A and CD8B and PD1 immune checkpoint blockades PD-L1 and PD-L2 
(Figure 7). We selected six cancer types (BRCA, BLCA, HNSC, LUAD, LUSC, and 
SKCM) with sufficient samples containing SCMs for adequate statistical power. Both T cell 
markers (PD-1, CD8A, and CD8B) and immune checkpoint blockade PD-L1 show increased 
expression in samples with SCMs compared to samples without SCMs (Figure 7), indicating 
alternative splice forms induced by SCMs increase the overall immunogenicity of these 
cancers. The highly expressed PD-L1 suggests PD-L1 immunotherapy as potential 
treatments for samples containing SCMs.
DISCUSSION
In this study, we applied our newly developed bioinformatics tool called MiSplice 
(mutation-induced splicing) to systematically analyze splice-site-creating events that arise 
from somatic mutations. Our analysis shows MiSplice reliably identifies SCMs across 
multiple cancer types. Existing studies have largely focused on splice-disrupting events in 
known splice sites, but the current study substantially extends our knowledge into the realm 
of SCMs in human cancer. For instance, we found 1,016 splice site mutations not only 
disrupt the canonical splice site but also create an alternative splice site. We also found that 
hundreds of mutations that would traditionally be classified as missense, silent, indel, and 
nonsense are really acting as SCMs. Many important cancer-related genes harbor these 
mutations, such as TP53, ATRX, BAP1, CTNNB1, RB1, etc. It is noteworthy that we found 
five SCMs in ATRX among 288 LGG cases, likely leading to the disruption of ATRX 
function. A previous study has shown that loss of wild-type ATRX is associated with tumor 
growth in glioma (Koschmann et al., 2016).
Characterization of these alternative splice events show that most SCMs have a higher splice 
score, as measured by MaxEntScan, in the post-mutation alternative splice site as compared 
to the reference. These results are consistent with the preferential selection of these 
alternative sites as new splicing forms. For the splice-site mutation, the splice score 
associated with the canonical junction is coincidently decreased after mutation. However, 
while there is no difference in splice scores of canonical junctions before and after missense 
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and silent mutations, the alternative splice site was often strengthened after mutation. This 
suggests silent and missense mutations instead act as modifiers of splicing by creating or 
strengthening cryptic sites within the exon as opposed to disrupting the canonical splice site. 
In addition, we found a significant enrichment of mutations at the −3 position in the 3′ 
splice site, the two dominant sequence contexts being aGag and agGag, where G is at the −3 
position.
In cases in which the mutation is retained in the alternative splice junction, we distinguish 
mutations with two further categories, splice-in and splice-out. For splice-in mutations, we 
can characterize the association between mutations and cryptic splicing forms. For example, 
we found high concordance for RNA-seq reads supporting alternatively spliced junctions 
and mutations, suggesting the association between mutations and cryptic splicing forms.
The current study has greatly extended insights into the transcriptional ramifications of 
genomic alterations by identifying nearly 1,964 alternative splice sites introduced by somatic 
mutations and functionally validating 10 of 11 variants in a mini-gene splicing assay. These 
events were conventionally annotated as missense, silent, splice site, nonsense, or other 
mutations when, in fact, we have shown that they often create cryptic splice sites. This 
relative abundance of the alternative and wild-type product suggests varying levels of 
junction usage, depending on the context of the mutation, and emphasizes the importance of 
validating predictions using a functional assay to understand the full biological consequence. 
The alternative products may be therapeutically targetable in some cancer patients. For 
example, targeting neoantigens shows promising results in treating melanoma patients 
(Carreno et al., 2015). By further evaluating human leukocyte antigen (HLA) genotypes and 
binding affinities to the MHC, it is likely that new neoantigens from cryptic splice sites may 
be discovered. The current study reveals that alternative splice forms induced by SCMs are 
highly immunogenic and correlated with a high T cell immune response and an elevated PD-
L1 expression, suggesting the potential for immunotherapy in these samples. Further 
investigation of the cryptic splice sites by mass spectra or target assay are needed to 
prioritize therapeutic targets in clinical trials.
STAR★METHODS
Detailed methods are provided in the online version of this paper and include the following:
• KEY RESOURCES TABLE
• CONTACT FOR REAGENT AND RESOURCE SHARING
• EXPERIMENTAL MODEL AND SUBJECT DETAILS
• METHOD DETAILS
◦ Dataset Description
◦ MiSplice Pipeline
◦ Splice Site Score Estimation
◦ Neoantigen Prediction
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◦ Manual Review
◦ Code Availability
◦ Mini-gene Splicing Assay
◦ Cell Culture
• QUANTIFICATION AND STATISTICAL ANALYSES
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Li Ding (lding@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Cancer Genome Atlas (TCGA) collected both tumor and non-tumor biospecimens from 
10,224 human samples (https://cancergenome.nih.gov/abouttcga/policies/informedconsent). 
Here, we use variants from a publicly available mutation annotation file (MAF) complied by 
the MC3 working group (syn7824274).
METHOD DETAILS
Dataset Description—Aligned RNA-seq bam files were analyzed using the ISB google. 
These cancer types are Acute Myeloid Leukemia [LAML], Adrenocortical carcinoma 
[ACC], Bladder Urothelial Carcinoma [BLCA], Brain Lower Grade Glioma [LGG], Breast 
invasive carcinoma [BRCA], Cervical squamous cell carcinoma and endocervical 
adenocarcinoma [CESC], Cholangiocarcinoma [CHOL], Colon adenocarcinoma [COAD], 
Esophageal carcinoma [ESCA], Glioblastoma multiforme [GBM], Head and Neck 
squamous cell carcinoma [HNSC], Kidney Chromophobe [KICH], Kidney renal clear cell 
carcinoma [KIRC], Kidney renal papillary cell carcinoma [KIRP], Liver hepatocellular 
carcinoma [LIHC], Lung adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC], 
Lymphoid Neoplasm Diffuse Large B cell Lymphoma [DLBC], Mesothelioma [MESO], 
Ovarian serous cystadenocarcinoma [OV], Pancreatic adenocarcinoma [PAAD], 
Pheochromocytoma and Paraganglioma [PCPG], Prostate adenocarcinoma [PRAD], Rectum 
adenocarcinoma [READ], Sarcoma [SARC], Skin Cutaneous Melanoma [SKCM], Stomach 
adenocarcinoma [STAD], Testicular Germ Cell Tumors [TGCT], Thymoma [THYM], 
Thyroid carcinoma [THCA], Uterine Carcinosarcoma [UCS], Uterine Corpus Endometrial 
Carcinoma [UCEC], Uveal Melanoma [UVM]
MiSplice Pipeline—The MiSplice pipeline was developed to detect mutation-induced 
splicing events from RNA-seq data. It is written in Perl and incorporates two standard tools, 
samtools and MaxEntScan. The pipeline is fully automated and can run multiple jobs in 
parallel on LSF cluster. It executes the following steps:
1. Splitting large maf file into multiple smaller files with less mutations (currently, 
the default setting is 200).
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2. Discovering splicing junctions within 20bps of the mutation with at least 5 
supporting reads with mapping quality Q20 and then filtering canonical junctions 
by using the Ensembl 37.75 database. We selected 20bp as a cut-off since it is the 
farthest distance from the splice junction in a splice region.
3. Computing the number of supporting reads of above cryptic splice sites for 
control samples without mutations (Table S1).
4. Calculating the splicing scores for the cryptic splice sites via MaxEntScan.
5. Reporting the depth of each cryptic splice site via Samtools.
6. Filtering cryptic sites which fall in HLA loci or less than 5% of reads at the 
genomic location supporting the alternative junction of interest.
7. Further filtering cryptic sites by comparing the supporting reads in control 
samples. The final reported cryptic sites must stand as top 5% for the number of 
supporting reads in the case (with mutation).
Splice Site Score Estimation—For each cryptic splice site and nearby canonical splice 
site, the corresponding nucleotide sequences were first extracted for both the mutant and 
reference sequences (9-mer and 23-mer for donor and acceptor, respectively). Their splice 
scores as potential donor or acceptor sites were then estimated using MaxEntScan.
Neoantigen Prediction—For each predicted SCM, we use a curated RefSeq transcript 
database (version 20130722) to obtain the translated protein sequences for transcript 
containing alternative splice forms induced by SCMs. Different length of epitopes (8-mer, 9-
mer, 10-mer and 11-mer) are constructed from the translated protein sequence. We use 
NetMHC3pan (Nielsen and Andreatta, 2016) and NetMHC4 (Andreatta and Nielsen, 2016) 
to predict the binding affinity between epitopes and MHC. Epitopes with binding affinity ≤ 
500nM which are also not present in the wild-type transcript are extracted from the 
following neoantigen analysis.
Manual Review—All splice-site-creating mutations were manually reviewed using the 
integrative genomics viewer (http://software.broadinstitute.org/software/igv/). Mutations 
were placed into one of three categories: Pass, Complex, and No Support. Mutations were 
classified as complex if more than one alternatively spliced product was observed for the 
mutated sample.
Code Availability—MiSplice is written in Perl and is freely available from GitHub at 
https://github.com/ding-lab/misplice under the GNU general public license. MiSplice uses 
several independent tools and packages, including SamTools and MaxEntScan, all of which 
are likewise freely available, but which must be obtained from their respective developers. 
The MiSplice documentation contains complete instructions for obtaining and linking these 
applications into MiSplice.
Mini-gene Splicing Assay—Exons of interest and approximately 150 bp of their 
flanking intron sequences were PCR amplified from HEK293T genomic DNA using primers 
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carrying restriction enzyme sites for BamH1 and MluI. PCR products were cleaned up using 
NucleoSpin PCR Cleanup (Macherey-Nagel) or DNA Clean and Concentrator-5 Kit (Zymo 
Research) and digested with BamHI and MluI. The digested pCAS2.1 vector and PCR 
products were ligated using T4 DNA Ligase (NEB). Mutations were introduced via Q5 Site-
Directed Mutagenesis (NEB). WT and MUT constructs were confirmed by sequencing of 
the insert region. The plasmids were transiently transfected into HEK293T cells using 
Lipofectamine 2000 (ThermoFisher Scientific). 24 hr post transfection, cDNA was 
synthesized using 2 to 3 ug of total RNA with the Superscript III First-Strand Synthesis 
System (ThermoFisher Scientific) and priming with Oligo(dT)20. Finally, cDNA was 
amplified using pCAS-KO1-(5′-TGACGTCGCCGCCCATCAC-3′) and pCAS-R (5′-
ATTGGTTGTTGAGTTGGTTGTC-3′) and the alternative splicing patterns were evaluated 
on a 2.5% agarose gel with ethidium bromide. Qiaquick Gel Extraction Kit (QIAGEN) was 
used to purify bands for sequencing (Figures S3, S4, S5, and S6; Tables S5, S6, and S7).
Cell Culture—HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with fetal bovine serum (FBS) and penicillin streptomycin.
QUANTIFICATION AND STATISTICAL ANALYSES
MiSplice assesses the significance of the number of reads supporting the predicted 
alternative splice junction by comparing to read counts from a control cohort. Specifically, a 
frequency distribution is constructed from the control cohort, from which threshold values 
for 5% and 95% tails on the left and right, respectively, are determined. A series of logic 
tests is then conducted to discern the best explanation of the data. Possible verdicts are low 
or high expression if the datum is outside the 5% or 95% thresholds, respectively, average 
expression if no thresholds are exceeded, or no expression in this tissue if the thresholds are 
zero.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• MiSplice applied to PanCancer data identifies 1,964 splice-site-creating 
mutations
• 26% and 11% of SCMs had been previously mis-annotated as missense and 
silent mutations
• SCMs may be more immunogenic than are missense mutations
• A mini-gene functional assay validates 10 of 11 predicted SCMs
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Figure 1. Splice-Site-Creating Mutation Discovery
(A) Examples of splice-site-creating mutations for different conventionally annotated 
mutation types. Splice-in is defined as mutations contained within the newly created exons, 
and splice-out is when the mutation is present in the newly created intron.
(B) The MiSplice workflow consists of three steps: alternative junction discovery, filtering, 
and manual review. First, the user inputs the locations of RNA-seq BAM files along with a 
mutation file. MiSplice searches the BAM file to identify any alternative splice junctions 
near the mutation of interest, while filtering out known splice junctions and calculating the 
number of alternative junction-supporting reads for case and control samples. For the 
filtering step, the following sites are removed: mutations in HLA genes, a low fraction of 
reads supporting the alternative splice junction, and sites expressed in controls. Finally, we 
manually reviewed all sites to validate the in silico predictions.
(C) Breakdown of 2,056 manually validated splice-site-creating mutations by conventional 
annotation.
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Figure 2. Sequence Contexts and Characteristics of Splice-Site-Creating Mutations
(A) Frequency distribution of splice-site-creating mutations relative to the newly created 
splice junction, with high frequency shown at the third nucleotide position in the newly 
created intron.
(B) Comparison of splicing scores for the newly created splice site, before (reference) and 
after the mutation (mutant). A larger effect of mutations at the third nucleotide position in 
the intron (especially for the 3′ splice sites) is shown.
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(C) Dominant nucleotide sequence context for splice-site-creating mutations at −3 position 
of the 3′ splice site. Mutation position (red dot) is present 3 base pairs away from the newly 
created exon.
(D) Transition and transversion rate at the −3 position of the 3′ splice site. Most mutations 
are G > C transversions, strengthening the consensus sequence of the splicing factor U2AF1.
(E) Comparison of splicing scores between the nearest canonical splice junction with and 
without a mutation compared to the newly created splice junction with and without a 
mutation. Most mutations strengthen the alternative splice junction relative to the canonical 
splice junction.
Jayasinghe et al. Page 21
Cell Rep. Author manuscript; available in PMC 2018 July 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Junction Allele Fraction of Splice-Site-Creating Mutations
(A) The junction allele fraction (JAF) is defined as the number of reads supporting the 
alternative spliced junction relative to total junction spanning reads. Distribution of JAF 
values separated by conventional annotation type.
(B) JAF versus DNA variant allele fraction (VAF) comparison by conventional annotation 
type. Most mutation types show a generally positive correlation between JAF and VAF 
values.
(C) Splice-site-creating mutations expressed in the newly created exon of the alternative 
splice junction. Comparison of mutation position relative to the percent of reads supporting 
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the alternative junction and mutation (spliced-in JAF). The mean of each position is 
highlighted by the black point. For all positions, there is a strong correlation between the 
presence of the splice-site-creating mutation and the alternative splice junction.
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Figure 4. Splice-Site-Creating Mutations across Genes and Cancer Types
(A) Distribution of splice-site-creating mutations in each gene separated by the total number 
of mutations in each gene. TP53 has the largest number of splice-site-creating mutations, 
followed by GATA3 and ATRX.
(B) Genes with the highest number of pancancer splice-site-creating mutations. Circle size 
correlates with the total number of mutations for each gene (labeled inside circle) and 
colored by cancer type. Splice-site-creating mutations in TP53 are present in many cancer 
types, while mutations in ATRX and GATA3 are specific to LGG and BRCA, respectively.
(C) Proteins Timeless (PAB domain) and PARP1 (chain A) are colored green and pink, 
respectively. Originally annotated p.S939S mutation (red) and spliced-out sequence (blue) 
are highlighted on PARP1 (chain A).
(D) 3D protein structure of PARP1 in complex with an inhibitor (PDB ID: 5WRQ). Drug 
inhibitor and PARP1 (chain A) are indicated in green and pink, respectively.
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Figure 5. Minigene Functional Assay of Splice-Site-Creating Mutations
(A) Integrative genomics viewer (IGV) screenshot of the conventionally annotated 
synonymous mutation in PARP1 in exon 21. RNA-seq reads of the candidate splice-site-
creating mutation reveal the creation of an alternative splice site (red reads) created by the 
conventionally annotated synonymous mutation.
(B) Candidate recurrent splice-site-creating mutations in BAP1. Conventionally annotated as 
synonymous variants, the BAP1-mutated region shows alternatively spliced reads (red reads) 
in the IGV screenshot for each sample with the splice-site-creating mutation.
(C) IGV screenshot of a conventionally annotated synonymous mutation in RAD51C in 
exon 2.
(D) Maximum entropy score of the splice-site-creating variant before (purple) and after (red) 
the introduced mutation for each variant functionally validated in the mini-gene splicing 
assay. In silico predictions suggest all mutations strengthen the alternative splice site.
(E) Candidate splice-site-creating mutations validated by the mini-gene splicing assay. 
Exons of interest were cloned into the pCAS2.1 vector and mutant (red); wild-type (purple) 
plasmids were transfected into 293T cells; and total RNA was extracted to identify mutation-
induced alternatively spliced products.
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Figure 6. Schematic of GATA3 Splice-Site-Creating Mutations and Neoantigen Predictions
(A) Distribution of neoantigens predicted by NetMHCpan and NetMHC4. Genes with the 
highest number of neoantigens labeled. Mean value for each tool indicated by X and labeled.
(B) Genes with the largest recurrence of predicted neoantigens across the dataset. GATA3 
shows the highest recurrence.
(C) Mutual exclusivity of protein-affecting mutation (PAM), frameshifting indel (FS), in-
frame indel (IF), and splice-site-creating mutations (SCM) in GATA3. (D) IGV screenshot 
of GATA3 splice-site-creating mutation, which disrupts the canonical splice site and utilizes 
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a cryptic splice site 7 bp downstream. Mutant reads highlighted in red, and normal reads are 
in purple. CA deletion indicated in the figure.
(E) Predicted functional domains disrupted because of the recurrent splice-site-creating 
mutation in GATA3.
(F) Predicted neoantigen peptide sequences mapped to the frameshifted protein product for 
samples with GATA3 SCMs.
(G) Mass spectrum of GATA3 peptide in TCGA-AR-A1AP.
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Figure 7. PD-L1, PD-L2, PD-1, CD8A, and CD8B Expression
(A) Expression comparison of PD-L1, PD-L2, and T cell markers PD-1, CD8A, and CD8B 
between samples with (case) and without (control) SCMs across six cancer types. p values: * 
less than 0.05; ** < 0.01; and *** < 0.001; ns, not significant.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
Human: HEK293T cells ATCC https://www.atcc.org/products/all/CRL-3216.aspx
Oligonucleotides
Primers for cDNA amplification pCAS-
KO1-(5′-
TGACGTCGCCGCCCATCAC-3′) pCAS-
R (5′-
ATTGGTTGTTGAGTTGGTTGTC-3′)
This paper N/A
Primers for Q5 mutagenesis and restriction 
enzyme primers for amplifying exons of 
interest see Table S6
This paper N/A
Recombinant DNA
Plasmid: pCAS2 Inserm Laboratory N/A
Software and Algorithms
MaxEntScan Yeo and Burge, 2004 http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html
Samtools Li et al., 2009 http://samtools.sourceforge.net/
MiSplice In preparation https://github.com/ding-lab/misplice
Integrative Genomics Viewer Robinson et al., 2011 http://software.broadinstitute.org/software/igv/
Chemicals, Peptides, and Recombinant 
Proteins
Nucleospin PCR Cleanup Macherey-Nagel 740609.10
DNA Clean and Concentrator-5 Kit Zymo Research D4003
BamHI New England Biomedicine R0136S
MluI New England Biomedicine R0198S
T4 DNA Ligase New England Biomedicine M0202S
Q5 Site Directed Mutagenesis New England Biomedicine E0554S
Lipofectamine 2000 Thermofisher Scientific 12566014
Superscript III First-Strand Synthesis 
System
Thermofisher Scientific 18080051
Qiaquick Gel Extraction Kit QIAGEN 28704
Other
Public MC3 MAF In preparation https://gdc.cancer.gov
MSGF+ N/A https://www.ncbi.nlm.nih.gov/pubmed/?term=25358478
Mass Spectra Data from 77 TCGA Breast 
Cancer Patients
N/A https://cptac-data-portal.georgetown.edu/cptac/s/S029
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